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High-affinity binding sites for glucagon-like peptide-I 7 36 amide (GLP-I 7-36 NH2) were identified in rat brain and 
lung membranes. Binding of [a25I]GLP-I 7 36 NH z was rapid, reversible, specific, saturable and pH dependent. Specific 
binding in the central nervous ystem was particularly high in the hypothalamus and the brain stem. Oxyntomodulin, 
glucagon-like peptide-l, glucagon-like peptide-2 and glucagon were 100-1000-fold ess potent han GLP-I 7-36 NH z in 
competition for this binding site. 
Glucagon-like peptide 7-36 amide; Receptor; (Brain, Lung) 
1. INTRODUCTION 
The proglucagon gene also encodes two peptides 
which share approx. 50°7o sequence homology with 
glucagon and are named glucagon-like peptide-1 
and -2 (GLP-1 and GLP-2) [1]. The GLP-1 se- 
quence is identical in hamster, man, ox and rat [2] 
and this high degree of sequence conservation sug- 
gests that GLP-1 has a significant biological role 
which has yet to be determined. Apart from its 
weak insulinotropic effect [3], the only known ac- 
tions of GLP-1 are its binding in the hypothalamus 
and pituitary and the subsequent adenylate cyclase 
activation [4,5]. While GLP-1 is the major process- 
ed form found in the pancreas a smaller fragment 
GLP-1 7-36 NHz predominates in the intestine [6]. 
GLP-1 7-36 NH2 occurs naturally, and is a potent 
stimulator of insulin secretion in the isolated rat 
pancreas [7], a rat ~-cell line [3], and the most po- 
tent insulinotropic hormone known in man [6]. 
The existence of GLP-1 7-36 NHz receptors in rat 
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insulinoma cell lines has been reported [8,9]. 
Recently we have reported the presence of GLP-1 
7-36 NH2 in the brain [10]. This peptide has also 
been shown to be a potent inhibitor of gastric acid 
secretion [11]. We have studied the binding of 
[tzsI]GLP-1 7-36 NHz in various tissues to obtain 
more information about the possible biological ac- 
tivities of GLP-1 7-36 NHz. 
2. MATERIALS AND METHODS 
2.1. Reagents 
Gastric inhibitory polypeptide (GIP), vasoactive intestinal 
polypeptide (VIP), peptide histidine methionine (PHM), GLP-1 
7-36 NHz, GLP-I, GLP-2, calcitonin gene-related peptide 
(CGRP), neuropeptide Y (NPY), and substance P (SP) were ob- 
tained from Peninsula Laboratories (Merseyside, England). Ox- 
yntomodulin was custom synthesized by Institute of Armand 
Frappier (Quebec, Canada) and pure porcine glucagon was ob- 
tained from Novo Research Institute (Copenhagen, Denmark). 
Tween 20 (polyoxyethylene-sorbitan mo olaurate) and bovine 
serum albumin (BSA) were obtained from Sigma (St. Louis, 
MO); protein assay reagent and BSA standards were obtained 
from Pierce (Rockford, IL). Carrier free NalZSI was obtained 
from Amersham International (Buckinghamshire, England). 
2.2. Tissue preparation 
Homogenization of tissues from Wistar rats was carried out 
in a 10-fold higher volume of ice cold 50 mM Tris-HC1 buffer 
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(pH 7.4) containing 0.32 M sucrose using an Ultra-Turrax 
homogenizer. The homogenate was centrifuged at 1000 x g for 
20 min and the resulting supernatant centrifuged at 50000 xg  
for 20 min. The pellet was resuspended in 50 mM Tris-HCl buf- 
fer (pH 7.4) containing 0.1 M NaC1. This was recentrifuged and 
the pellet resuspended in Tris-HCI buffer at a final protein con- 
centration of 1-3/zg/,ul. Protein content was estimated by the 
Coomassie blue dye method with BSA as standard [12]. 
2.3. Preparation and analysis of the radioligand ff251]GLP-1 
7-36 NH2 
GLP-1 7-36 NH2 was iodinated by the chloramine T method 
[13] and purified by HPLC.  In a typical experiment the follow- 
ing were added sequentially: 10 ,ug of  GLP-1 7-36 NH2 in 50,ul 
of 0.4 M sodium phosphate buffer (pH 7.4); 10/A of 1 mCi 
Nat25I solution; 10/A of chloramine T (0.45 raM). After 10 s the 
reaction was stopped by adding 25 tzl sodium metabisulphite (1 
mM). The reaction mixture was diluted with 20070 (v/v) aqueous 
acetonitrile (ACN) containing 0.1 070 (v/v) TFA and loaded on a 
C 18 reverse-phase column which was equilibrated with the same 
solution. Optimal separation of [~25I]GLP-1 7-36 NHz was 
achieved by elution with an isocratic gradient of 42070 ACN. 
Specific activity of the tracer was checked by radioimmunoassay 
as described previously [6]. 
2.4. Binding assays 
Under standard conditions, the binding assays were perform- 
ed in a final volume of 0.5 ml of 50 mM Tris-HC1 buffer (pH 
7.4) containing BSA (0.307o w/v), MgCI2 (5 mM), EDTA (2 
mM), Tween 20 (0.0507o v/v), membranes (200/~g), [~251]GLP-1 
7-36 NH2 (60 fmol) and unlabelled competing peptides as 
specified. Membranes were incubated at 18°C for 90 min and 
the separation of bound and free radioactivity was carried out 
by centrifugation at 12000xg for 2.5 min in a microfuge. The 
supernatant was removed and the radioactivity in the pellet 
counted. Specific (saturable) binding was calculated as the dif- 
ference between the amount of [~251]GLP-1 7-36 NHz bound in 
the absence (total binding) and presence of 0.1/~M unlabelled 
GLP-I  7-36 NH2 (non-saturable binding). Scatchard plots were 
analysed by linear regression to determine dissociation constant 
(Kd) and the binding capacity (Bmax)- 
3. RESULTS 
Chloramine T iodination and HPLC purifica- 
tion of the label consistently gave a single peak of 
radioactivity. This peak had a specific activity of 
500-1500 Ci/mmol. Initial experiments howed 
that the label was adsorbed strongly to the reaction 
tubes (polypropylene, Eppendorf). This was mini- 
mised by adding 0.05°7o Tween 20 to the incubation 
buffer as described by Paul et al. [14]. 
In preliminary experiments we observed high 
levels of binding in the lung and brain and very low 
levels of binding in the liver, pancreas, adipose 
tissues, stomach mucosa, and spleen. No binding 
could be detected in the thyroid gland, adrenal 
gland, kidney, skeletal muscle and ileal smooth 
muscle. 
Specific binding of [125I]GLP-1 7-36 NH2 to rat 
brain membranes reached a maximum after 90 min 
and was maintained for the next 60 min. Addition 
of 0.1 /zM cold peptide to membranes, in equili- 
brium with the label, caused a rapid displacement 
of the bound label (fig.l). 
The stability of the ligand upon incubation with 
membranes was investigated by studying its elution 
characteristics on HPLC. After 90 min incubation 
with membranes at 18°C nearly all the radioactivi- 
ty eluted in the same position as [125I]GLP-1 7-36 
NH2. 
The binding of [125I]GLP-1 7-36 NH2 to brain 
and lung membranes was pH dependent and max- 
imum binding was observed at pH 7.4. 
A survey of the regional distribution of [1251]- 
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Fig.l .  Time course of [~251]GLP-1 7-36 NHzassociation and 
dissociation to brain stem membranes. Dissociation was 
initiated by addition of native GLP-I  7-36 NH2 to give a final 
concentration of  0.1 ,uM (indicated by arrow). 
Table 1 
Regional distribution of [~25I]GLP-1 7-36 NH2 binding sites in 
the brain (mean +_ SE, n = 5) 
Region Specific binding (07o of total 
[125IlGLP-1 7-36 NH2 added) 
Hypothalamus 1.85 + 0.25 
Medulla oblongata 1.32 + 0.31 
Midbrain 1.28 + 0.19 
Pons 1.02 _+ 0.20 
Pituitary gland 0.78 _+ 0.11 
Cerebellum 0.18 + 0.04 
Cerebral cortex 0.12 _+ 0.04 
Olfactory bulb 0.05 _+ 0.04 
Binding is expressed as °/0 of tracer that is specifically bound per 
50,ug of  protein 
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GLP-1 7-36 NHz-binding sites in the brain (table 1) 
was performed. These values represent determina- 
tions at a single ligand concentration (60 fmol) 
rather than B . . . .  High specific binding in the brain 
was observed in the hypothalamus and the brain 
stem region whereas the cortex and cerebellum 
showed negligible binding. 
To determine the specificity of GLP-1 7-36 
NHz-binding sites, a variety of peptides were tested 
for their ability to inhibit [~25I]GLP-1 7-36 NH2 
binding to brain stem and lung membranes. The 
patterns of displacement were similar in the brain 
stem and lungs (fig.2A and B). CGRP, SP, NPY, 
VIP, PHM, GIP did not interact with the GLP-1 
7-36 receptor at concentrations up to 1/zM. The 
order of potency of the peptides from the glucagon 
gene was oxyntomodulin > GLP-1 and GLP-2 > 
glucagon. 
The concentration dependence of GLP-1 7-36 
1.000 
"5 
"R 
~ 0.500 
"5 
._~ ~d 
t~ 
O.OOG 
-11 
- " - " ~r"" ~" iz "~"  i '~ ..~ ='-~ 1"~! -  Glucogon "".'~.-/t~ ~ ~-- .  
o ~ , ""'R',.x \ \ ~....:, \ .  
~o Oxyntomodulin"\ '"N. \ 
\ 4" 
*'. "-~ • GLP-2 \ '.. o 
' * . .  ~ GLP-1 
GLP-1 7-36, °"'.-.,.~.~)..,.~.o, o * 
-i0 -9 -8 -7 g8 
-- Log (peptide concentration) 
1.000 
._ 
e~ 
0 
~_ 0.500 
U3 
"5 E 
.g 
~d 
U_ 
0.000 
-11 
B 
\ ., 
x ".~ 
ax, x ,. ~:, \ .  \ o~.to ~ 
b modulln \. '.~Q 
"\ ~\ 
~o "x "",\ GLP-2 
- 10 -9 --8 -7 -6 
- Log (peptide concentration) 
Fig.2. Inhibition of [~ZSl]GLP-1 7-36 NHE binding in the 
brainstem (A) and lung (B) by increasing concentrations of 
various peptides. Binding is expressed as a fraction of specific 
binding obtained in the presence of [~25I]GLP-1 7-36 NH2 
alone. Results show the mean of three experiments in triplicate 
(SE< 10%). 
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Fig.3. Scatchard analysis of GLP-1 7-36 NHz binding in the 
brain stem and the lung. Dissociation curve data obtained with 
increasing concentration of native GLP-1 7-36 NH2 as in fig.2A 
and B were transformed to give a Scatchard plot. 
NHz binding to rat brain and lung membranes was 
determined by adding increasing concentrations of
unlabelled GLP-1 7-36 NHz. Scatchard analysis of 
these data revealed a curve indicating two popula- 
tions of binding sites in the brain stem with a 
dissociation constant (Kd) of 0.47 + 0,08 and 15 + 
5.2 nM and a maximum binding capacity (Bmax) of 
35 +-- 9 and 130 + 32 fmol/mg of protein. There 
was one class of binding sites in the lungs with a Kd 
of 2.5 + 0.9 nM and a Bmax of 560 + 46 fmol/mg 
of protein (fig.3). 
4, DISCUSSION 
The interaction of GLP-1 7-36 NHz with rat 
brain and lung membranes satisfied the generally 
accepted criteria for a peptide hormone and recep- 
tor interaction. 
The high density of binding sites for GLP-1 7-36 
NHz observed in the hypothalamus correlates well 
with the high density of GLP-I-  and glucagon- 
binding sites at this location [4]. Glucagon and 
Glp-1 are also localized in this particular egion of 
the brain [4,10,15]. In the hypothalamus peptides 
from the preproglucagon gene may play a role in 
the regulation of pancreatic hormone release [16]. 
The order of potency of related peptides in com- 
peting with GLP-1 7-36 NHz was similar in the 
brain stem and lung suggesting that the receptor 7 
binding sites in these tissues are similar. GLP-1 and 
GLP-2 were equipotent in displacing GLP-1 7-36 
NHz from its receptor at a 100-fold lower potency 
than GLP-1 7-36 NHz. Oxyntomodulin showed 
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higher crossreactivity han glucagon for the bin- 
ding site. The conformation of glucagon and oxyn- 
tomodulin is different from that deduced from 
competition data [17,18] and this could also ac- 
count for their different interactions with the 
GLP-1 7-36 receptor. This property of oxyn- 
tomodulin and GLP-1 to interact with the GLP-I 
7-36 NH2 receptor could account for their weak in- 
sulinotropic activity [19] and also their effect on 
cAMP production in mucosal cells [11]. 
The presence of GLP-1 7-36 NHz receptors at 
multiple locations in the body increases the possi- 
bility of other functions for this newly discovered 
hormone. 
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